Merit Medical Systems Company Profile (NASDAQ:MMSI)

Merit Medical Systems trades on the NASDAQ under the ticker symbol "MMSI."

Merit Medical Systems, Inc. (NASDAQ:MMSI) announced its quarterly earnings results on Wednesday, July, 26th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.07. The business had revenue of $186.50 million for the quarter, compared to analyst estimates of $181.46 million. Merit Medical Systems had a net margin of 4.87% and a return on equity of 9.78%. The company's revenue was up 23.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 EPS. View Merit Medical Systems' Earnings History.

Merit Medical Systems is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Merit Medical Systems.

Merit Medical Systems updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.23-$1.28 for the period, compared to the Thomson Reuters consensus estimate of $1.18. The company issued revenue guidance of $722-$727 million, compared to the consensus revenue estimate of $720.13 million.

8 analysts have issued 1-year price targets for Merit Medical Systems' stock. Their forecasts range from $20.00 to $50.00. On average, they expect Merit Medical Systems' stock price to reach $39.59 in the next year. View Analyst Ratings for Merit Medical Systems.

Here are some recent quotes from research analysts about Merit Medical Systems stock:

• 1. According to Zacks Investment Research, "Merit Medical Systems, Inc. was formed for the purpose of producing single-use medical products of high quality and superior value primarily for use in diagnosis and treatment of cardiovascular disease. The company's products are designed to provide physicians and other health care professionals with devices that enable them to perform interventional and diagnostic procedures safely and effectively. " (6/22/2017)
• 2. Canaccord Genuity analysts commented, "We maintain our Buy rating on shares of MMSI but lower, albeit modestly, our price target from $35 to $33.50 due to modest dilution to our forward EPS targets from the recently completed secondary offering. To wit, the company completed a public offering of 4,500,000 shares of common stock at a price of $28.25 per share last Wednesday. The company raised nearly $125M in order to pay down some of its outstanding long term debt, which stood at $314M as of year-end 2016, including $180M revolving credit loans outstanding, not including an additional $38M of revolving credit loans to finance the Catheter connections purchase in early 1Q17. We see the secondary offering as prudent and necessary in order to remain at required leverage ratios. In short, we retain our thesis that stronger top-line revenue growth and expanding gross margins should continue to drive double-digit earnings growth – notwithstanding the offering dilution to share count – for the next few years at least." (3/27/2017)

Some companies that are related to Merit Medical Systems include Taro Pharmaceutical Industries (TARO), Hikma Pharmaceuticals Plc (HKMPF), Mednax (MD), ACADIA Pharmaceuticals (ACAD), Integra LifeSciences Holdings Corporation (IART), Mallinckrodt PLC (MNK), Patterson Companies (PDCO), Clovis Oncology (CLVS), NuVasive (NUVA), Opko Health (OPK), ICU Medical (ICUI), Molina Healthcare (MOH), Portola Pharmaceuticals (PTLA), Sage Therapeutics (SAGE), Insulet Corporation (PODD), Cantel Medical Corp. (CMD), Nektar Therapeutics (NKTR) and Hutchison China MediTech Limited (HCM).

Merit Medical Systems' management team includes the folowing people:

• Fred P. Lampropoulos, Chairman of the Board, President, Chief Executive Officer
• Bernard J. Birkett, Chief Financial Officer, Treasurer
• Joseph C. Wright, President - International Division
• Ronald A. Frost, Chief Operating Officer
• Justin J. Lampropoulos, Executive Vice President - Sales, Marketing and Strategy
• Brian G. Lloyd, Chief Legal Officer, Corporate Secretary
• Nolan E. Karras, Lead Independent Director
• David Ming-Teh Liu, Director
• Kent W. Stanger, Director
• A. Scott Anderson, Independent Director

Merit Medical Systems' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.64%), Vanguard Group Inc. (8.76%), Frontier Capital Management Co. LLC (5.48%), Dimensional Fund Advisors LP (5.39%), Ameriprise Financial Inc. (3.20%) and Janus Henderson Group PLC (3.06%). Company insiders that own Merit Medical Systems stock include A Scott Anderson, F Ann Millner, Franklin J Miller, Kent W Stanger, Michael E Stillabower, Nolan E Karras and Richard W Edelman. View Institutional Ownership Trends for Merit Medical Systems.

Merit Medical Systems' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Marshall Wace North America L.P., Voya Investment Management LLC, Goldman Sachs Group Inc., Tudor Investment Corp ET AL, Ameriprise Financial Inc. and Argent Capital Management LLC. Company insiders that have sold Merit Medical Systems stock in the last year include A Scott Anderson, F Ann Millner, Franklin J Miller, Kent W Stanger, Michael E Stillabower, Nolan E Karras and Richard W Edelman. View Insider Buying and Selling for Merit Medical Systems.

Merit Medical Systems' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Frontier Capital Management Co. LLC, AMI Asset Management Corp, Russell Investments Group Ltd., Koch Industries Inc., Fiera Capital Corp, Columbus Circle Investors and Vanguard Group Inc.. View Insider Buying and Selling for Merit Medical Systems.

Shares of Merit Medical Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Merit Medical Systems stock can currently be purchased for approximately $40.85.